Open Nav

Axolo Pharma

  • Thomas Krol, Axolo Pharma

Series A Raise

  • Date:Wednesday, October 17
  • Time:10:15 AM - 10:30 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Axolo Pharma, Inc. is a joint venture between Trim-edicine, Inc. and Novadiol, Inc. Trim-edicine is a spinout of The Ohio State University. Novadiol is a biotech company with significant drug development experience. Axolo desires to help people through new science and has the worldwide rights (x-China) to the injectable use of MG53. Discovered by Dr. Jianjie Ma and colleagues, MG53 is a cellular repair protein. Originally discovered in muscle cells, it has a unique mechanism of action resulting in rapid healing of cellular injury due to trauma, toxin or immune mediated damage. MG53 has applications for diseases of the brain, heart, kidney, muscle, and lung. Initial development targets in include orphan diseases such as delayed graft function and ALS.
  • Company Website:https://axolopharm.com/regenerate/
  • Company HQ City:Shawnee, KS
  • Company HQ Country:United States
  • Company HQ State:Kansas                       
  • CEO/Top Company Official:Gerard Wood
  • Year Founded:2018
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development :MG53
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:To date MG53 has been tested in animal models of ischemia/reperfusion injury and cellular trauma. The MG53 protein has shown positive outcomes in models of stroke, myocardial infarction, acute lung injury, acute kidney injury, MS, Duchenne MD, and ALS. MG53 is a critical element of membrane repair and mitochondrial preservation. These two activities allow for cellular preservation in situations where they would normally become injured and die, which would produce end organ damage. As a regenerative medicine, MG53 acts to spare injured cells from death, which results in significantly less end organ damage.
  • Previous and Current Investors:NIH
  • Size of Last Investment Round:NA
  • Total Amount Raised to Date, In All Rounds:0 (JV Companies > $10 million)
Speakers
Thomas Krol
Axolo Pharma
Back